FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896751119> ?p ?o ?g. }

• W2896751119 abstract "The most frequent site of recurrence in breast cancer (BC) is the bone, particularly in patients with ‘luminal‑like’ disease. Denosumab has been shown to prevent aromatase inhibitors (AIs) induced bone resorption in postmenopausal early BC patients and reduce skeletal‑related events (SREs) in bone metastatic breast cancer (BMBC). A ‘real life’ analysis of 90 BMBC patients treated with denosumab was performed. Eighty‑six patients (95.6%) had ‘luminal‑like’ disease, 72 (80%) had bone metastases at the time of first recurrence of disease. Among 50 patients with metachronous ‘luminal‑like’ disease, 40 (80%) had first recurrence to the bone. Among these patients median time to skeletal recurrence (TSkR) was shorter for patients who were previously exposed to AIs compared to those who were not (53.0 vs. 102.0 months, respectively; P=0.0300) and longer for patients previously treated with tamoxifen compared to those who were not (102.0 vs. 59.0 months, respectively; P=0.0466). Both of them were not confirmed at multivariate analysis. In the overall population, 17 first SREs were observed (16 radiation therapy) and median time to first SRE was not reached. A statistically significant difference in the incidence of SREs was detected only between patients with exclusively osteolytic bone metastases vs. those without (P=0.013). The presence of exclusively‑osteolytic bone metastases was the only factor significantly associated with a shorter time to first SRE (P=0.011). The only G3 toxicity reported was hypocalcemia in one patient. No osteonecrosis of the jaw events (ONJ) occurred. This study demonstrated that a pro‑active attitude enables the treatment of the majority of patients with denosumab without significant class‑related toxicities. The majority of SREs were from radiation therapy, so pain still remains the clinical hallmark of bone metastases, particularly for osteolytic ones. The suggestion that estrogen deprivation with AIs can favor a ‘bone‑related’ risk conditions for developing bone metastases must be considered with caution and surely needs further validations." @default.
• W2896751119 created "2018-10-26" @default.
• W2896751119 creator A5004742126 @default.
• W2896751119 creator A5010067465 @default.
• W2896751119 creator A5020344479 @default.
• W2896751119 creator A5025150226 @default.
• W2896751119 creator A5027420799 @default.
• W2896751119 creator A5030010530 @default.
• W2896751119 creator A5039992416 @default.
• W2896751119 creator A5051041229 @default.
• W2896751119 creator A5055028865 @default.
• W2896751119 creator A5060772629 @default.
• W2896751119 creator A5060914868 @default.
• W2896751119 creator A5060954139 @default.
• W2896751119 creator A5073192545 @default.
• W2896751119 creator A5083621831 @default.
• W2896751119 creator A5085894499 @default.
• W2896751119 creator A5090705680 @default.
• W2896751119 creator A5091765229 @default.
• W2896751119 date "2018-10-10" @default.
• W2896751119 modified "2023-10-01" @default.
• W2896751119 title "The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis‑generator’ study from clinical practice" @default.
• W2896751119 cites W1589316426 @default.
• W2896751119 cites W1607511023 @default.
• W2896751119 cites W163336082 @default.
• W2896751119 cites W1883044208 @default.
• W2896751119 cites W1965434694 @default.
• W2896751119 cites W1971211622 @default.
• W2896751119 cites W1973039656 @default.
• W2896751119 cites W1975798559 @default.
• W2896751119 cites W1982915376 @default.
• W2896751119 cites W1985038642 @default.
• W2896751119 cites W1985727076 @default.
• W2896751119 cites W1986471913 @default.
• W2896751119 cites W2014530124 @default.
• W2896751119 cites W2015776299 @default.
• W2896751119 cites W2026850151 @default.
• W2896751119 cites W2039834660 @default.
• W2896751119 cites W2057993678 @default.
• W2896751119 cites W2061897981 @default.
• W2896751119 cites W2094599068 @default.
• W2896751119 cites W2100291515 @default.
• W2896751119 cites W2102969047 @default.
• W2896751119 cites W2104599723 @default.
• W2896751119 cites W2116760308 @default.
• W2896751119 cites W2120608859 @default.
• W2896751119 cites W2122786185 @default.
• W2896751119 cites W2137539267 @default.
• W2896751119 cites W2143879648 @default.
• W2896751119 cites W2147946257 @default.
• W2896751119 cites W2148439716 @default.
• W2896751119 cites W2165011173 @default.
• W2896751119 cites W2170309090 @default.
• W2896751119 cites W2187668060 @default.
• W2896751119 cites W2235523093 @default.
• W2896751119 cites W2290195878 @default.
• W2896751119 cites W2414332811 @default.
• W2896751119 cites W2505286088 @default.
• W2896751119 cites W2557222435 @default.
• W2896751119 cites W2610710927 @default.
• W2896751119 cites W2794671383 @default.
• W2896751119 cites W2796557635 @default.
• W2896751119 cites W2800590229 @default.
• W2896751119 cites W4210331534 @default.
• W2896751119 cites W4293241248 @default.
• W2896751119 doi "https://doi.org/10.3892/ol.2018.9561" @default.
• W2896751119 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6256706" @default.
• W2896751119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30546457" @default.
• W2896751119 hasPublicationYear "2018" @default.
• W2896751119 type Work @default.
• W2896751119 sameAs 2896751119 @default.
• W2896751119 citedByCount "3" @default.
• W2896751119 countsByYear W28967511192021 @default.
• W2896751119 countsByYear W28967511192022 @default.
• W2896751119 countsByYear W28967511192023 @default.
• W2896751119 crossrefType "journal-article" @default.
• W2896751119 hasAuthorship W2896751119A5004742126 @default.
• W2896751119 hasAuthorship W2896751119A5010067465 @default.
• W2896751119 hasAuthorship W2896751119A5020344479 @default.
• W2896751119 hasAuthorship W2896751119A5025150226 @default.
• W2896751119 hasAuthorship W2896751119A5027420799 @default.
• W2896751119 hasAuthorship W2896751119A5030010530 @default.
• W2896751119 hasAuthorship W2896751119A5039992416 @default.
• W2896751119 hasAuthorship W2896751119A5051041229 @default.
• W2896751119 hasAuthorship W2896751119A5055028865 @default.
• W2896751119 hasAuthorship W2896751119A5060772629 @default.
• W2896751119 hasAuthorship W2896751119A5060914868 @default.
• W2896751119 hasAuthorship W2896751119A5060954139 @default.
• W2896751119 hasAuthorship W2896751119A5073192545 @default.
• W2896751119 hasAuthorship W2896751119A5083621831 @default.
• W2896751119 hasAuthorship W2896751119A5085894499 @default.
• W2896751119 hasAuthorship W2896751119A5090705680 @default.
• W2896751119 hasAuthorship W2896751119A5091765229 @default.
• W2896751119 hasBestOaLocation W28967511191 @default.
• W2896751119 hasConcept C121608353 @default.
• W2896751119 hasConcept C126322002 @default.
• W2896751119 hasConcept C126894567 @default.
• W2896751119 hasConcept C141071460 @default.
• W2896751119 hasConcept C143998085 @default.
• W2896751119 hasConcept C2776286101 @default.

• next